William Guyer - 01 Oct 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
Issuer symbol
CORT
Transactions as of
01 Oct 2024
Net transactions value
-$246,300
Form type
4
Filing time
03 Oct 2024, 16:27:05 UTC
Previous filing
05 Sep 2024
Next filing
05 Nov 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $216,500 +10,000 +173% $21.65 15,796 01 Oct 2024 Direct F1
transaction CORT Common Stock Sale $462,800 -10,000 -63% $46.28 5,796 01 Oct 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -10,000 -2.1% $0.000000 460,000 01 Oct 2024 Common Stock 10,000 $21.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
F3 Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.